ALGEN Stock Overview
A biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
genOway Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.92 |
| 52 Week High | €4.91 |
| 52 Week Low | €3.24 |
| Beta | 0.53 |
| 1 Month Change | 5.09% |
| 3 Month Change | 3.16% |
| 1 Year Change | -13.66% |
| 3 Year Change | -11.01% |
| 5 Year Change | 208.66% |
| Change since IPO | -34.78% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That genOway Société anonyme (EPA:ALGEN) Is Using Debt Reasonably Well
Jun 08
genOway Société anonyme's (EPA:ALGEN) Price Is Right But Growth Is Lacking
Jan 20We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Sep 27We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
May 31We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Nov 01Shareholder Returns
| ALGEN | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.0% | -3.8% | -0.6% |
| 1Y | -13.7% | -31.6% | -4.0% |
Return vs Industry: ALGEN exceeded the French Biotechs industry which returned -30.2% over the past year.
Return vs Market: ALGEN underperformed the French Market which returned -4.1% over the past year.
Price Volatility
| ALGEN volatility | |
|---|---|
| ALGEN Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALGEN has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALGEN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 128 | Alexandre Fraichard | www.genoway.com |
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines.
genOway Société anonyme Fundamentals Summary
| ALGEN fundamental statistics | |
|---|---|
| Market cap | €35.32m |
| Earnings (TTM) | €1.26m |
| Revenue (TTM) | €28.08m |
28.1x
P/E Ratio1.3x
P/S RatioIs ALGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGEN income statement (TTM) | |
|---|---|
| Revenue | €28.08m |
| Cost of Revenue | €12.36m |
| Gross Profit | €15.72m |
| Other Expenses | €14.47m |
| Earnings | €1.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 55.99% |
| Net Profit Margin | 4.47% |
| Debt/Equity Ratio | 35.9% |
How did ALGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 02:51 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
genOway Société anonyme is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guillaume Cuvillier | Gilbert Dupont |
| Arnaud Guérin | Portzamparc BNP Paribas |